Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 18/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL20608292 | 0.99 | SIGMAR1 (0.98) | SIGMAR1ATMKDM4EKCNH2 | |
| Oxalic Acid SCHEMBL1899223 | 0.95 | SIGMAR1 (0.91) | SIGMAR1ATMKDM4EKCNH2 | |
| SCHEMBL467442 | 0.84 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| SCHEMBL20608293 | 0.83 | SIGMAR1 (0.71) | SIGMAR1KCNH2 | |
| Oxalic Acid SCHEMBL1896893 | 0.81 | SIGMAR1 (0.88) | SIGMAR1ATMKCNH2 | |
| SCHEMBL467023 | 0.80 | SIGMAR1 (1.00) | SIGMAR1KDM4EKCNH2 | |
| SCHEMBL1899226 | 0.79 | SIGMAR1 (0.65) | SIGMAR1ATMKCNH2 | |
| Oxalic Acid SCHEMBL1896480 | 0.77 | SIGMAR1 (0.88) | SIGMAR1KDM4EKCNH2 | |
| SCHEMBL466979 | 0.76 | SIGMAR1 (0.88) | SIGMAR1KCNH2 | |
| Hydrochloric Acid SCHEMBL1903312 | 0.75 | SIGMAR1 (0.86) | SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010128-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2019-01-10 | — | — | US | claimed |
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | claimed |
| US-20160310501-A1 | GABAPENTINOIDS AND SIGMA RECEPTOR LIGANDS COMBINATIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-10-27 | — | — | US | claimed |
| US-20160310500-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-10-27 | — | — | US | claimed |
| EP-3082782-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-10-26 | — | — | EP | claimed |
| EP-3082790-A1 | GABAPENTINOIDS AND SIGMA RECEPTOR LIGANDS COMBINATIONS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-10-26 | — | — | EP | claimed |
| US-20160220574-A1 | NSAID AND SIGMA RECEPTOR LIGAND COMBINATIONS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-08-04 | — | — | US | claimed |
| EP-3043795-A1 | NSAID AND SIGMA RECEPTOR LIGAND COMBINATIONS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-07-20 | — | — | EP | claimed |
| US-20160151377-A1 | USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS) | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-06-02 | — | — | US | claimed |
| EP-3013338-A1 | USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS) | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-05-04 | — | — | EP | claimed |
| EP-2460519-A1 | Use of sigma ligands in bone cancer pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-06-06 | — | — | EP | claimed |
| WO-2012016980-A2 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-02-09 | — | — | WO | claimed |
| EP-2415471-A1 | Use of sigma ligands in opioid-induced hyperalgesia | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-02-08 | — | — | EP | claimed |
| WO-2011144721-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-24 | — | — | WO | claimed |
| EP-2388005-A1 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-11-23 | — | — | EP | claimed |
| WO-2011095585-A1 | SIGMA LIGANDS FOR POTENTIATING THE ANALGESIC EFFECT OF OPIOIDS AND OPIATES IN POST-OPERATIVE PAIN AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-11 | — | — | WO | claimed |
| EP-2353591-A1 | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | claimed |
| US-20110112095-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-12 | — | — | US | claimed |
| US-20100190780-A1 | SIGMA RECEPTOR INHIBITORS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-07-29 | — | — | US | claimed |
| US-20080125416-A1 | Sigma Receptor Inhibitors | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2008-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310500-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | SIGMAR1, OPRL1, SLC6A2 | SIGMAR1 1/4885ATM 3998/4885KDM4E 4133/4885 |
| US-20160151377-A1 | USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS) | OPRL1, NPSR1, SIGMAR1 | SIGMAR1 3/4885ATM 4400/4885KDM4E 4832/4885 |
| US-20160310501-A1 | GABAPENTINOIDS AND SIGMA RECEPTOR LIGANDS COMBINATIONS | SIGMAR1, OPRL1, OPRM1 | SIGMAR1 1/4885ATM 4344/4885KDM4E 4594/4885 |
| US-20080125416-A1 | Sigma Receptor Inhibitors | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885ATM 4081/4885KDM4E 4559/4885 |
| US-20190010128-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | OPRK1, OPRD1, SIGMAR1 | SIGMAR1 3/4885ATM 4489/4885KDM4E 2955/4885 |
| US-20110112095-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | OPRK1, OPRD1, SIGMAR1 | SIGMAR1 3/4885ATM 4489/4885KDM4E 2955/4885 |
| US-20160220574-A1 | NSAID AND SIGMA RECEPTOR LIGAND COMBINATIONS | SIGMAR1, OPRL1, OPRK1 | SIGMAR1 1/4885ATM 4035/4885KDM4E 4811/4885 |
| US-20100190780-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885ATM 4081/4885KDM4E 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.